

PHD ORAL DEFENSE

Roles of SR proteins-mediated Splicing in Modulating Chemotherapy Resistance

Cisplatin is a broadly used chemodrug that suppresses cancer growth. But, the acquisition of resistance by cancer cells is an inherent problem with the use of cisplatin. Hence, it is critical to elucidate the mechanism of chemoresistance to treat the cancers more effectively. In this study, we proposed that alteration in mRNA splicing landscape could be adopted by cancer cells to overcome cisplatin-induced cytotoxicity. We developed two different cisplatin-resistant breast cancer cell lines to compare the splicing profiling between sensitive and resistant cancer cells. In particular, SRSFs and their kinases SRPKs were found to be differentially expressed in response to cisplatin in sensitive and resistant cancer cells. Moreover, post-translational modifications, especially the acetylation of SRPK1 mediated by Tip60, was found to regulate cellular responses to cisplatin. The adaptive changes on acetylation of SRPK1 affects the RNA splicing such as *BCL2L1* and *MCL1* due to hyperactive SRSFs. Therefore, our study implies that SRPK1 and its relevant splicing regulation could be one of the key mechanisms that result in chemoresistance to cisplatin in breast cancer cells.

Friday

14 June 2019

10.00am - 11.30am

Seminar Room, MD10

Level 2, Anatomy Museum

WANG CHENGGraduate Student
Anatomy, NUS Medicine